Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

ROCKET AF Investigators, Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, Günter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox, Robert M Califf

Research output: Contribution to journalArticlepeer-review


The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
Original languageEnglish
Pages (from-to)883-891
Number of pages9
JournalNew England Journal of Medicine
Issue number10
Publication statusPublished - 2011


Dive into the research topics of 'Rivaroxaban versus warfarin in nonvalvular atrial fibrillation'. Together they form a unique fingerprint.

Cite this